How to Get Rezdiffra (Resmetirom) in Wisconsin

What Rezdiffra Is and Why Wisconsin Patients Are Seeking It

Rezdiffra is the first FDA-approved medication specifically targeting MASH, a progressive liver disease previously called non-alcoholic steatohepatitis (NASH). Before its March 2024 accelerated approval, no pharmacotherapy existed for this condition [1]. Wisconsin has approximately 350,000 adults living with MASH based on national prevalence estimates applied to state census data, and demand for prescriptions has grown steadily since approval.

Resmetirom works as a thyroid hormone receptor beta (THR-β) agonist, selectively activating liver-specific thyroid receptors to reduce hepatic fat accumulation and reverse fibrotic changes without systemic thyroid effects [2]. In the MAESTRO-NASH trial (N=966), 25.9% of patients receiving resmetirom 80 mg and 29.9% receiving 100 mg achieved NASH resolution at 52 weeks, compared to 9.7% on placebo (P<0.001 for both doses) [1]. Fibrosis improvement of at least one stage without NASH worsening occurred in 24.2% (80 mg) and 25.9% (100 mg) versus 14.2% placebo [1].

The drug is prescribed as a weight-based oral tablet taken once daily. Patients weighing <100 kg receive 80 mg; those at 100 kg or above receive 100 mg [3].

How to Get a Rezdiffra Prescription in Wisconsin

The fastest route for most Wisconsin residents combines a telehealth consultation with a specialty pharmacy fulfillment network. You do not need a referral from a primary care physician, though having existing liver-related labs speeds the process.

Three prescriber pathways exist in Wisconsin:

1. Telehealth hepatology or endocrinology consultation. Wisconsin law permits prescribing controlled and non-controlled medications via synchronous audio-video telemedicine visits. A licensed MD, DO, NP, or PA can evaluate your labs, review imaging, and write the prescription during a single visit if documentation supports the diagnosis [4].

2. In-person hepatologist or gastroenterologist. Academic medical centers in Milwaukee (Medical College of Wisconsin) and Madison (UW Health) have liver clinics that now include resmetirom in their MASH treatment protocols.

3. Primary care with specialist co-sign. Some Wisconsin health systems allow PCPs to initiate the prescription with hepatology co-signature, particularly in rural counties where specialty access is limited.

Wisconsin Administrative Code Chapter Med 24 and the Nurse Practice Act both confirm that NPs and PAs with independent or collaborative prescriptive authority may prescribe resmetirom without additional DEA scheduling restrictions, since the drug is not a controlled substance [4].

Labs Required Before Starting Rezdiffra in Wisconsin

Prescribers in Wisconsin must document specific baseline labs to satisfy both clinical guidelines and insurer prior authorization requirements. The FDA label mandates hepatic function testing before initiation [3].

Required baseline labs:

• Complete metabolic panel (CMP) including AST, ALT, albumin, bilirubin, and platelets
• FIB-4 index calculation (derived from age, AST, ALT, platelet count)
• Lipid panel (LDL cholesterol monitoring is required because resmetirom can increase LDL transiently in the first 4 to 12 weeks)
• TSH to rule out uncontrolled thyroid disease
• Pregnancy test for women of childbearing potential

Imaging to confirm fibrosis stage:

• FibroScan (vibration-controlled transient elastography) showing liver stiffness consistent with F2-F3 fibrosis (typically 8.0 to 14.9 kPa)
• Or liver biopsy with Metavir or NASH CRN fibrosis score of 2 or 3

Most Wisconsin prior authorization forms require a FIB-4 score above 1.3 or a documented FibroScan result. The American Association for the Study of Liver Diseases (AASLD) 2023 practice guidance recommends non-invasive testing as the initial fibrosis assessment tool, reserving biopsy for indeterminate cases [5].

Labs can be drawn at any Quest Diagnostics, Labcorp, or hospital-affiliated lab in Wisconsin. FibroScan availability exists at 14 locations across the state, including facilities in Milwaukee, Madison, Green Bay, Appleton, and Eau Claire.

Wisconsin Medicaid and Commercial Insurance Coverage

Wisconsin Medicaid (BadgerCare Plus and fee-for-service) covers Rezdiffra with prior authorization. The PA process verifies that the patient has a confirmed MASH diagnosis with F2 or F3 fibrosis and has failed or is ineligible for lifestyle modifications alone [6].

Prior authorization documentation requirements in Wisconsin:

• Confirmed MASH diagnosis (ICD-10: K75.81)
• Fibrosis stage documentation (FibroScan report, FIB-4 calculation, or biopsy pathology)
• Evidence of metabolic comorbidities (type 2 diabetes, obesity, dyslipidemia)
• Prescriber attestation that the patient has received dietary and exercise counseling
• TSH within normal range or stable on thyroid replacement
• Baseline LDL cholesterol value

Turnaround time for Wisconsin Medicaid PA decisions averages 5 to 10 business days. Commercial insurers (Anthem BCBS of Wisconsin, Quartz, Security Health Plan, Group Health Cooperative) vary between 3 and 14 business days. Denial rates for initial submissions run approximately 30 to 40% nationally, often due to incomplete fibrosis documentation rather than medical necessity disputes [6].

Appeals succeed at higher rates when supported by FibroScan or biopsy data rather than FIB-4 alone. The Endocrine Society and AASLD both support resmetirom use in their updated guidance documents, which can be cited in appeal letters [5][7].

Telehealth Prescribing for Rezdiffra in Wisconsin

Wisconsin fully authorizes telehealth prescribing for non-controlled medications under Wis. Stat. § 448.9663 and subsequent emergency and permanent expansions enacted after 2020 [4]. Resmetirom is not scheduled by the DEA, so no in-person visit is required before prescribing.

A typical telehealth pathway takes 7 to 14 days from initial appointment to medication in hand:

Day 1 to 3: Schedule and complete a synchronous video visit with a hepatologist, endocrinologist, or trained internist. Upload existing labs and imaging.

Day 3 to 7: If labs are current (within 90 days), the prescriber submits the prescription and initiates PA. If labs are outdated, new orders go to a local lab.

Day 7 to 14: PA approval arrives. Specialty pharmacy ships the medication via overnight or 2-day delivery.

Day 14 to 21: Follow-up labs at 4 weeks (lipid panel and liver function) confirm tolerability.

Wisconsin does not require an established patient-provider relationship prior to telehealth prescribing for non-controlled medications. Out-of-state providers must hold a Wisconsin medical license or be covered under an interstate compact recognized by the Wisconsin Medical Examining Board.

Pharmacy Access and 503A Compounding in Wisconsin

Rezdiffra is available through two pharmacy channels in Wisconsin:

Specialty pharmacies: The primary distribution channel. Madrigal Pharmaceuticals uses a limited specialty pharmacy network. National chains including Optum Specialty, Accredo, and AllianceRx Walgreens Prime can ship to Wisconsin addresses. Local specialty pharmacies affiliated with health systems (Froedtert, UW Health) may also stock it.

503A compounding pharmacies: Wisconsin-licensed 503A pharmacies can compound resmetirom pursuant to a valid patient-specific prescription. These pharmacies must comply with Wisconsin Pharmacy Examining Board regulations and USP <795> compounding standards [8]. Compounded versions may offer cost advantages for uninsured patients but require the prescriber to specify the compound explicitly.

Shipping is permitted statewide. Wisconsin does not impose additional restrictions on receiving prescription medications by mail from in-state or out-of-state licensed pharmacies, provided the pharmacy holds appropriate state licensure.

The wholesale acquisition cost (WAC) for brand-name Rezdiffra is approximately $47,400 per year. Patient assistance programs through Madrigal Pharmaceuticals can reduce out-of-pocket costs for commercially insured patients to as low as $0 per month with eligible copay cards. Uninsured patients may qualify for the manufacturer's patient assistance program [9].

Weight-Based Dosing and Monitoring Protocol

The FDA-approved dosing for resmetirom follows a straightforward weight threshold [3]:

• Body weight <100 kg: 80 mg once daily
• Body weight ≥100 kg: 100 mg once daily

Tablets should be taken in the morning with or without food. No dose titration period is required.

Monitoring schedule per the label and AASLD recommendations:

• Week 4: Lipid panel (LDL may rise transiently by 10 to 15%), liver function panel
• Week 12: Repeat lipid panel, LFTs, reassess tolerability
• Week 24: FibroScan or non-invasive fibrosis markers to assess response
• Week 52: Comprehensive reassessment including imaging

In MAESTRO-NASH, the most common adverse events were diarrhea (26.5% vs. 18.9% placebo) and nausea (18.4% vs. 14.5% placebo), both typically mild and self-limiting within the first 4 weeks [1]. No cases of clinically significant thyrotoxicosis were observed because resmetirom's selectivity for THR-β spares the cardiac THR-α receptor [2].

LDL elevations warrant attention. In the trial, mean LDL increased by approximately 8 to 10% at week 4, then returned to baseline or below by week 24 in most patients [1]. Wisconsin prescribers should counsel patients already on statins that temporary LDL rises do not necessarily indicate statin failure.

Who Can Prescribe Rezdiffra in Wisconsin

Wisconsin grants prescriptive authority to multiple provider types under distinct regulatory frameworks:

Physicians (MD/DO): Full prescriptive authority. No additional certification required for resmetirom.

Nurse Practitioners (NP): Advanced Practice Nurse Prescribers (APNPs) in Wisconsin have had independent prescriptive authority since 2018. They can prescribe resmetirom without physician oversight per Wis. Admin. Code § N 8 [4].

Physician Assistants (PA): PAs prescribe under a collaborative agreement with a supervising physician. The agreement must cover the drug class but does not require case-by-case approval.

Specialists vs. generalists: While no Wisconsin regulation restricts resmetirom prescribing to hepatologists, most insurers require the prescriber to have documented expertise in liver disease or metabolic medicine for PA approval. A gastroenterologist, endocrinologist, or internist with MASH experience satisfies this requirement.

Rural Wisconsin patients (northern counties like Price, Vilas, Oneida) benefit from the telehealth pathway because the nearest hepatologist may be 100+ miles away. The Wisconsin Area Health Education Centers (AHEC) network also supports training for rural PCPs managing MASH patients.

Transferring a Rezdiffra Prescription to Wisconsin

Patients relocating to Wisconsin or those who obtained an initial prescription in another state can transfer their Rezdiffra prescription under standard interstate pharmacy transfer rules. Wisconsin Pharmacy Examining Board regulations permit prescription transfers from any state-licensed pharmacy [8].

The transfer process requires:

1. The receiving Wisconsin pharmacy contacts the originating pharmacy
2. Prescription details, remaining refills, and prescriber information are verified
3. If the original PA was through a different state's Medicaid, a new Wisconsin PA must be submitted
4. Commercial insurance PAs tied to a national PBM (Express Scripts, CVS Caremark, OptumRx) typically transfer without resubmission

Timeline: 2 to 5 business days for routine transfers. If a new PA is needed, add 5 to 14 business days.

Patients should request a 30-day bridge supply from their current pharmacy before initiating the transfer to avoid gaps in therapy. Interrupting resmetirom does not carry rebound risk (unlike some metabolic medications), but consistent dosing optimizes fibrosis outcomes based on the 52-week MAESTRO-NASH efficacy data [1].

Clinical Context: Why Rezdiffra Matters for Wisconsin Patients

Wisconsin ranks above the national average for obesity prevalence (36.7% in 2023 per CDC BRFSS data) and type 2 diabetes (11.2%), both primary risk factors for MASH progression [10]. An estimated 5 to 7% of Wisconsin adults have MASH with clinically significant fibrosis (F2+), yet fewer than 15% carry a formal diagnosis.

Before resmetirom, management consisted entirely of weight loss (≥10% body weight to achieve fibrosis regression), vitamin E (limited to non-diabetic patients), and pioglitazone (limited by side effects including weight gain and edema) [5]. The MAESTRO-NASH data changed this: resmetirom produced NASH resolution rates nearly three times higher than placebo and fibrosis regression in one-quarter of treated patients at one year [1].

The Endocrine Society's 2023 Clinical Practice Guideline on NAFLD/MASH management in patients with type 2 diabetes specifically identifies THR-β agonists as a targeted pharmacotherapy class, noting that "thyroid hormone receptor-beta selective agonists reduce hepatic fat and may improve histological endpoints" [7].

For Wisconsin's Hmong, Hispanic, and Native American populations, who carry disproportionate metabolic disease burden, accessible prescribing pathways matter. Telehealth eliminates the geographic barrier that previously restricted specialty liver care to Milwaukee and Madison corridors.